Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 25
In Progress Trials by Phase 26
Clinical Trials by Trial Status 27
Clinical Trials by End Point Status 28
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials 33
Prominent Drugs 35
Latest Clinical Trials News on Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) 36
Sep 11, 2017: Pharming Announces Conclusion of FDA End of Phase 2 Interactions on RUCONEST for Prophylaxis of HAE 36
Sep 05, 2017: BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE 36
Aug 02, 2017: BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks 37
Jul 26, 2017: Pharming Announces Publication of RUCONEST Prophylactic Data in The Lancet 37
Clinical Trial Profile Snapshots 38
Appendix 93
Abbreviations 93
Definitions 93
Research Methodology 94
Secondary Research 94
About GlobalData 95
Contact Us 95
Source 95
List of Tables
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Region, 2017* 8
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 12
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 16
Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, G7 Countries (%), 2017* 18
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, E7 Countries (%), 2017* 22
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Phase, 2017* 25
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 26
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 28
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 29
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 30
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 35
List of Figures
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 12
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 16
Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, G7 Countries (%), 2017* 17
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, E7 Countries (%), 2017* 21
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 25
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 26
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 28
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 29
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 30
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 35
GlobalData Methodology 94
